Jörg T. Hartmann - Concepedia

Author

Jörg T. Hartmann

Also Known As

J T Hartmann, Jorg T. Hartmann, Jörg Thomas Hartmann, JÖRG T. HARTMANN, Jörg T Hartmann, Jörg T. Hartmann, Jörg Thomas Hartmann

111

Publications

13.9K

Citations

H-Index

Concepts

All Affiliations

University of Tübingen Heidelberg University University Hospital Heidelberg Universität Hamburg University Medical Centre Mannheim

About

Jörg T. Hartmann is an author at University of Tübingen specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	24	6.4K
2	Gastroenterology	4	4	2.6K
3	Health Sciences	3	3	553
4	Cell Biology	2	2	52
5	Hepatology	2	2	989

Jörg T. Hartmann

Publications

12.2K

Citations

H-Index

Page 1

	Year	Citations
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk, The Lancet Surgical OncologyEsophageal CancerGastrointestinal OncologyMedicineVersus Fluorouracil	2019	2.4K
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer Helmut Oettle, P. Neuhaus, Andreas Hochhaus, JAMA	2013	1.8K
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Ian Judson, Jaap Verweij, Hans Gelderblom, The Lancet Oncology Metastatic Soft-tissue SarcomaVersus Intensified DoxorubicinOncologyMalignant DiseasePathology	2014	1.1K
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, JAMA	2012	955
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein, The Lancet Oncology HepatologyGastrointestinal OncologyMedicineColorectal CancerPathology	2009	953
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial Ralf‐Dieter Hofheinz, Frederik Wenz, Stefan Post, The Lancet Oncology Radiation TherapyGastrointestinal OncologyMedicineAdvanced Rectal CancerCancer Treatment	2012	501
Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis Carsten Bokemeyer, Craig R. Nichols, J P Droz, Journal of Clinical Oncology	2002	497
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk, JAMA Oncology	2017	458
MYC High Level Gene Amplification Is a Distinctive Feature of Angiosarcomas after Irradiation or Chronic Lymphedema Johanna Manner, Bernhard Radlwimmer, Peter Hohenberger, American Journal Of Pathology Lymphoid NeoplasiaDistinctive FeatureHistopathologyPathologyChronic Lymphedema	2009	314
Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy—Results From an International Study Group Karim Fizazi, Sergei Tjulandin, Roberto Salvioni, Journal of Clinical Oncology	2001	279

Page 1